World Investment Advisors grew its stake in Stryker Corporation (NYSE:SYK – Free Report) by 56.9% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,085 shares of the medical technology company’s stock after buying an additional 6,195 shares during the quarter. World Investment Advisors’ holdings in Stryker were worth $5,614,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. bought a new stake in Stryker in the 4th quarter valued at $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter valued at about $28,000. Institutional investors own 77.09% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. BTIG Research reduced their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.
Stryker Price Performance
NYSE:SYK opened at $326.41 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a market cap of $125.13 billion, a P/E ratio of 37.78, a P/E/G ratio of 2.09 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock’s 50-day simple moving average is $309.80 and its 200 day simple moving average is $338.87.
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.
Insider Activity at Stryker
In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by corporate insiders.
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles
- Five stocks we like better than Stryker
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
